Comparison of Four Intensive Care Scores in Prediction of VA-ECMO

Status Recruiting

Clinical Trial Summary

VA-ECMO is increasingly utilized in the setting of cardiogenic shock or cardiac arrest to restore hemodynamic stability and end organ function. VA-ECMO serves as a short-term ventricular assist device that can be rapidly placed at the bedside in the emergency room, intensive care unit, cardiac catheterization suite, or operating room. A bridge to decision approach allows for the assessment of neurologic status, renal and hepatic function, and subsequent recovery of cardiac function. Despite its life-saving potential, VA-ECMO is fraught with complications including vascular complications from cannulation. In addition, neurologic injury, renal failure, liver failure, and sepsis are all well described sequelae of the post-cardiogenic shock or cardiac arrest VA-ECMO patient. For these reasons, identifying early prognostic indicators and developing a score with regard to the outcome of this special patient population is of high interest. The proposed study aims to analyze 4 ICU scores/Survival prediction models [APACHE-II (acute physiology and chronic health evaluation II), SAVE (Survival after VA ECMO) , SOFA (sequential organ failure assessment )and CASUS (Cardiac Surgery Score)] and evaluate their performance in predicting survival after VA ECMO insertion. This will be a clinical retrospective study which will be conducted in the Cardiothoracic Intensive Care unit (CTICU) in the Department of Cardiothoracic Surgery, Heart Hospital, Doha. Patients admitted to the CTICU after institution of VA ECMO in the period between 1st January 2015 to 31st October 2022 will be screened retrospectively. Patients who stay for at least 12 hours in the CTICU would be eligible for inclusion in the study. All charts of patients who were admitted to CTICU after institution of VA ECMO during the afore mentioned period will be included in the review. All the risk scores would be calculated separately for all the enrolled patients and then subjected to statistical analysis to determine predictive accuracy for survival.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cardiogenic Shock
Extracorporeal Membrane Oxygenation Complication
Shock, Cardiogenic

Clinical Trial Details

NCT number	NCT05730881
Study type	Observational
Source	Hamad Medical Corporation
Contact	Suraj Sudarsanan, MD
Phone	44395897
Email	Sudarsanan@hamad.qa
Status	Recruiting
Phase
Start date	March 30, 2023
Completion date	November 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03283995` - Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
Active, not recruiting	`NCT04325035` - The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock	Phase 2
Active, not recruiting	`NCT05100836` - SURPASS Impella 5.5 Study
Not yet recruiting	`NCT05106491` - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients	N/A
Completed	`NCT02301819` - ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock	N/A
Completed	`NCT01367743` - Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock	Phase 4
Recruiting	`NCT05728359` - Genomic Determinants of Outcome in Cardiogenic Shock
Recruiting	`NCT05699005` - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO	Phase 1
Not yet recruiting	`NCT06338345` - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients	N/A
Completed	`NCT03436641` - Microcirculation in Cardiogenic Shock
Recruiting	`NCT03313687` - SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
Recruiting	`NCT05506449` - The RECOVER IV Trial	N/A
Completed	`NCT04144660` - "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Completed	`NCT04548739` - Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Recruiting	`NCT04141410` - Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
Not yet recruiting	`NCT05879276` - Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.	Phase 3
Enrolling by invitation	`NCT05570864` - Score TO Predict SHOCK - STOP SHOCK
Completed	`NCT02591771` - Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock	Phase 2
Terminated	`NCT02279979` - Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial	N/A
Completed	`NCT01374867` - CardShock Study and Registry	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparison of Four Intensive Care Scores in Prediction of VA-ECMO Survival. — ECMO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms